Emvenio Clinical Research
Emvenio Clinical Research is recorded as a service provider in 7 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 7 of 7 trials · Latest update first
An Open-Label, Long Term Safety and Efficacy Study of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE).
Sponsor Ionis Pharmaceuticals Inc.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase 3, Parallel-group Treatment, Blinded, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria due to Cystathionine Beta Synthase Deficiency (HARMONY)
Sponsor Travere Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Randomized, Double-Blind, Dose Finding and Comparison Study of the Safety and Efficacy of High Doses of Eteplirsen, Preceded by an Open-Label Dose Escalation, in Patients with Duchenne Muscular Dystrophy With Deletion Mutations Amenable to Exon 51 Skipping
Sponsor Sarepta Therapeutics Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Open-Label, Ascending Dose, Multicentre Study to Evaluate the Safety and Preliminary Efficacy of AVB-101 Administered by Bilateral Intrathalamic Infusion in Subjects With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
Sponsor Aviadobio Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 days to less than 18 years of Age with Autosomal Recessive Polycystic Kidney Disease (ARPKD).
Sponsor Otsuka Pharmaceutical Development & Commercialization Inc.
- Start (EU)
- Latest update
- Estimated end
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of Weekly Intravenous Infusions of BMN 351 in Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
Sponsor Biomarin Pharmaceutical Inc.
- Start (EU)
- Latest update
- Estimated end
A Double-Blind, Randomized, Multicenter, Trial Evaluating the Efficacy and Safety of PRAX-628 in Adults with Focal Seizures (POWER 1)
Sponsor Praxis Precision Medicines Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Emvenio Clinical Research?
The 2026-10-09 snapshot links Emvenio Clinical Research to 7 distinct CTIS trials. Recorded services include Home health, Home Health Care, Home Health Nursing Support, Home Health Vendor / Telehealth, among 6 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Emvenio Clinical Research?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Allergy, Immunology, Metabolic Disorders. Recorded phases include Phase 3, Phase 1, Phase 2. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Emvenio Clinical Research conducted?
The linked trials record locations in 18 countries, including Spain, Italy, Poland, Belgium, Germany. These are trial locations, not confirmed office locations or countries where Emvenio Clinical Research delivered services.
What can this page tell me about Emvenio Clinical Research's trial experience?
Browse 7 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Emvenio Clinical Research. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Emvenio Clinical Research LLC